Last updated on September 2018

Clinical Study to Compare the Efficacy and Safety of Ponesimod to Placebo in Subjects With Active Relapsing Multiple Sclerosis Who Are Treated With Dimethyl Fumarate (Tecfidera®)

Brief description of study

A clinical research study called 'POINT' will evaluate if adding an oral study drug to Tecfidera® can have an effect on multiple sclerosis (MS) disease activity.

In this study, patients with active relapsing MS will receive add-on therapy with ponesimod (a sphingosine 1-phosphate [S1P] receptor modulator) or placebo on top of background treatment with another oral MS drug (dimethyl fumarate [DMF] - Tecfidera®).

Eligible participants must currently take Tecfidera® and have taken this medication for at least 6 months. The primary objective of the study is to determine whether add-on therapy with ponesimod reduces relapse frequency as compared to placebo in subjects with active relapsing MS who are treated with Tecfidera®.

Clinical Study Identifier: TX203815

Find a site near you

Start Over